KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Common Equity: 2009-2025

Historic Common Equity for Neogenomics (NEO) over the last 16 years, with Sep 2025 value amounting to $838.3 million.

  • Neogenomics' Common Equity fell 7.70% to $838.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $838.3 million, marking a year-over-year decrease of 7.70%. This contributed to the annual value of $902.3 million for FY2024, which is 4.16% down from last year.
  • Neogenomics' Common Equity amounted to $838.3 million in Q3 2025, which was down 1.84% from $854.0 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Common Equity ranged from a high of $1.1 billion in Q2 2021 and a low of $838.3 million during Q3 2025.
  • For the 3-year period, Neogenomics' Common Equity averaged around $913.6 million, with its median value being $915.9 million (2024).
  • As far as peak fluctuations go, Neogenomics' Common Equity skyrocketed by 75.53% in 2021, and later dropped by 10.93% in 2022.
  • Over the past 5 years, Neogenomics' Common Equity (Quarterly) stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then decreased by 5.66% to $941.5 million in 2023, then declined by 4.16% to $902.3 million in 2024, then decreased by 7.70% to $838.3 million in 2025.
  • Its Common Equity stands at $838.3 million for Q3 2025, versus $854.0 million for Q2 2025 and $888.3 million for Q1 2025.